ข้อเสนอการใช้ภูมิคุ้มกันบําบัดไรฝุ่นชนิดอมใต้ลิ้นและชนิดฉีดเข้าใต้ผิวหนังในการรักษาโรคจมูกอักเสบภูมิแพ้และโรคจมูกอักเสบภูมิแพ้ร่วมกับโรคหืดในสถานการณ์การระบาดของโควิด-19

Prayuth Poowaruttanawiwit; Chanida Chantim; Klaita Srisingh

Authors

Prayuth Poowaruttanawiwit Department of Pharmacy Practice, Faculty of Pharmacy, Naresuan University
Chanida Chantim Department of Otolaryngology, Faculty of Medicine, Naresuan University
Klaita Srisingh Department of Pediatrics, Faculty of Medicine, Naresuan University

Keywords:

allergen immunotherapy, allergic rhinitis, allergic asthma, sublingual, subcutaneous

Abstract

The COVID-19 outbreak greatly disrupted healthcare systems and made it more difficult for patients to access treatment, ultimately affecting the quality of life of patients and society. This paper highlighted the issues and importance of policy management and examined the financial cost and social benefits of treating allergic rhinitis and allergic asthma caused by house dust mites (HDM) amid an outbreak of COVID-19. A comparative analysis was executed between HDM sublingual immunotherapy (SLIT) as an intervention and subcutaneous immunotherapy (SCIT) as a comparator. It was found that HDM SLIT provided a better return on investment from the perspective of society during the COVID-19 pandemic in 2021 than HDM SCIT. The benefit to cost (B/C) ratio of the HDM SLIT to HDM SCIT was 1.72 and likely to be less than 1.00, respectively, which were statistically different. Policymakers could use these results to establish strategies for treating allergic rhinitis with and without asthma by choosing between HDM SLIT and SCIT, particularly during the pandemic.

References

Plagg B, Piccoliori G, Oschmann J, Engl A, Eisendle K. Primary health care and hospital management during COVID-19: lessons from Lombardy. Risk Manag Healthc Policy 2021;14:3987-92.

Benfante A, Principe S, Cicero MN, Incandela M, Durante C, Scichilone N, Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: tips for facing the second wave. Pulm Pharmacol Ther 2022;73-4:102083.

Nadar SK, Tayebjee MH, Stowasser M, Byrd JB. Managing hypertension during the COVID-19 pandemic. J Hum Hypertens 2020;34(6):415-7.

Narita K, Hoshide S, Tsoi K, Siddique S, Shin J, Chia YC, et al. Disaster hypertension and cardiovascular events in disaster and COVID-19 pandemic. J Clin Hypertens (Greenwich) 2021;23(3):575-83.

Nogueira GM, Oliveira MS, Moura AF, Cruz CMS, Moura-Neto JA. COVID-19 in dialysis units: a comprehensive review. World J Virol 2021;10(5):264-74.

Negm AM, Salopek A, Zaide M, Meng VJ, Prada C, Chang Y, et al. Rehabilitation care at the time of coronavirus disease-19 (COVID-19) pandemic: a scoping review of health system recommendations. Front Aging Neurosci 2022;13:781271.

González-Montero J, Valenzuela G, Ahumada M, Barajas O, Villanueva L. Management of cancer patients during COVID-19 pandemic at developing countries. World J Clin Cases 2020;8(16):3390-404.

Alvaro-Lozano M, Sandoval-Ruballos M, Giovannini M, Jensen-Jarolim E, Sahiner U, Tomic Spiric V, et al. Allergic patients during the COVID-19 pandemic-Clinical practical considerations: an European Academy of Allergy and Clinical Immunology survey. Clin Transl Allergy 2022;12(1):e12097.

Yeğit OO, Demir S, Ünal D, Olgaç M, Terzioğlu K, Eyice Karabacak D, et al. Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic. Allergy 2022;77(1):197-206.

Aytekin ES, Soyer Ö, Şekerel BE, Şahiner ÜM. Subcutaneous allergen immunotherapy in children: real life compliance and effect of COVID-19 pandemic on compliance. Int Arch Allergy Immunol 2021;182(7):631-6.

Koca Kalkan I, Ates H, Aksu K, Yesilkaya S, Topel M, Cuhadar Ercelebi D, et al. Real-life adherence to subcutaneous immunotherapy: what has changed in the era of the COVID-19 pandemic. World Allergy Organ J 2021;14(7):100558.

Ozturk AB, Baççıoğlu A, Soyer O, Civelek E, Şekerel BE, Bavbek S. Change in allergy practice during the COVID-19 pandemic. Int Arch Allergy Immunol 2021;182(1):49-52.

Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect 2021;82(3):329-38.

Gani F, Cottini M, Landi M, Berti A, Comberiati P, Peroni D, et al. Allergic rhinitis and COVID-19: friends or foes? Eur Ann Allergy Clin Immunol 2022;54(2):53-9.

Ren J, Pang W, Luo Y, Cheng D, Qiu K, Rao Y, et al. Impact of allergic rhinitis and asthma on COVID-19 infection, hospitalization, and mortality. J Allergy Clin Immunol Pract 2022;10(1):124-33.

Vezir E, Hizal M, Cura Yayla B, Aykac K, Yilmaz A, Kaya G, et al. Does aeroallergen sensitivity and allergic rhinitis in children cause milder COVID-19 infection? Allergy Asthma Proc 2021;42(6):522-9.

Yucel E, Suleyman A, Hizli Demirkale Z, Guler N, Tamay ZU, Ozdemir C. ‘Stay at home’: Is it good or not for house dust mite sensitized children with respiratory allergies? Pediatr Allergy Immunol 2021;32(5):963-70.

Burrows AG, Ellis AK. Psychological impacts of coronavirus disease 2019 on people with asthma, allergic rhinitis, and food allergy. Ann Allergy Asthma Immunol 2022;129(1):52-61.

Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI Guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy 2019;74(5):855-73.

Ridolo E, Incorvaia C, Ciprandi G. Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria. Acta Biomed 2021;92(2):e2021194.

Yang L, Zhu R. Immunotherapy of house dust mite allergy. Hum Vaccin Immunother 2017;13(10):2390-6.

Wongsa C, Phinyo P, Sompornrattanaphan M, Krikeerati T, Lumkul, M, Thongngarm T. Efficacy and safety of house dust mite sublingual immunotherapy tablet in allergic asthma: a systematic review of randomized controlled trials. J Allergy Clin Immunol Pract 2022;10(5):1342-55.

Tortajada-Girbés M, Mesa Del Castillo M, Larramona H, Lucas JM, Álvaro Lozano M, Tabar AI, et al. Decision-making for pediatric allergy immunotherapy for aeroallergens: a narrative review. Eur J Pediatr 2019;178(12):1801-12.

Phinyo P, Krikeerati T, Wongyikul P, Lao-Araya M, Thongngarm T. House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: a systematic review and meta-analysis. Asian Pac J Allergy Immunol 2022;40(4):337-52.

Poowaruttanawiwit P. Cost effectiveness analysis of sublingual immunotherapy in the treatment of patients with house dust mite induced allergic rhinitis and allergic asthma comparing with standard treatment in Thailand. TJPP 2022;14(2):276-88.

Tsai Y, Vogt TM, Zhou F. Patient characteristics and costs associated with COVID-19-related medical care among Medicare fee-for-service beneficiaries. Ann Intern Med 2021;174(8):1101-9.

Blumenthal D, Jacobson GA. Putting Medicare spending for COVID-19 into perspective. Ann Intern Med 2021;174(8):1169-70.

Muschol J, Gissel C. COVID-19 pandemic and waiting times in outpatient specialist care in Germany: an empirical analysis. BMC Health Serv Res 2021;21(1):1076.

Passalacqua G, Nowak-Węgrzyn A, Canonica GW. Local side effects of sublingual and oral Immunotherapy. J Allergy Clin Immunol Pract 2017;5(1):13-21.

Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 2017;72(12):1825-48.

James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55-9.

Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG, et al. ARIA working group. 2019 ARIA care pathways for allergen immunotherapy. Allergy 2019;74(11):2087-102.

Klimek L, Chaker AM, Mösges R. Costs of allergic diseases and saving potential by allergen-specific immunotherapy: a personal assessment. HNO 2017;65(10):801-10.

Yepes-Núñez JJ, Gómez C, Espinoza Y, Cardona R. The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma. Biomedica 2014;34(2):282-90.

Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, Breiteneder H, et al. COVID-19 pandemic: practical considerations on the organization of an allergy clinic-An EAACI/ARIA position paper. Allergy 2021;76(3):648-76.

Green W, McMaster J, Babela R, Buchs S. Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European countries. Eur Ann Allergy Clin Immunol 2019;51(2):68-74.

Brüggenjürgen B, Reinhold T. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland. J Med Econ 2018;21(4):374-81.